Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13518 | 0.85 | ALDH1A1 (0.48) | ATMALDH1A1KMT2ACA1CA2 | |
| SCHEMBL4990371 | 0.82 | ATM (0.47) | ATMALDH1A1KMT2AEPHX1LTA4H | |
| SCHEMBL13711847 | 0.82 | ATM (0.50) | ATMALDH1A1KMT2ACA2LTA4H | |
| SCHEMBL2484332 | 0.82 | ATM (0.50) | ATMALDH1A1KMT2ACA2LTA4H | |
| SCHEMBL13711848 | 0.82 | ATM (0.50) | ATMALDH1A1KMT2ACA2LTA4H | |
| SCHEMBL6189242 | 0.81 | CPN1 (0.53) | ATMCA1CA2EPHX1 | |
| SCHEMBL5197131 | 0.81 | CA1 (0.48) | ALDH1A1KMT2ACA1CA2EPHX1 | |
| SCHEMBL13747226 | 0.80 | ATM (0.48) | ATMALDH1A1KMT2ACA2LTA4H | |
| SCHEMBL16328249 | 0.80 | ATM (0.44) | ATMALDH1A1KMT2ALTA4HMETAP2 | |
| SCHEMBL11078577 | 0.79 | ATM (0.45) | ATMALDH1A1KMT2AEPHX1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | ATM 3295/4885ALDH1A1 1846/4885KMT2A 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.